Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Age-related macular degeneration (AMD) is a common cause of severe vision loss in people 55 years and older. OBJECTIVES: The objective of this review was to investigate the effects of anti-VEGF (vascular endothelial growth factor) modalities for treating neovascular AMD. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, EMBASE and LILACS. We handsearched ARVO abstracts for 2006, 2007 for ongoing trials. SELECTION CRITERIA: We included randomized controlled trials (RCTs). DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data. We contacted trial authors for additional data. We summarized outcomes as relative risks (RR), number needed to treat (NNT) and weighted mean differences. MAIN RESULTS: We included five RCTs of good methodological quality. All five trials were conducted by pharmaceutical companies. An intention-to-treat analysis using the last observation carried forward method was done in most trials. Two trials compared pegaptanib versus sham. One trial compared ranibizumab versus sham, another compared ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and the final trial compared ranibizumab plus verteporfin PDT versus verteporfin PDT alone. Fewer patients treated with pegaptanib lost 15 or more letters of visual acuity at one year follow-up compared to sham (pooled relative risk (RR) 0.71; 95% confidence interval (CI) 0.61 to 0.84). The NNT was 6.67 (95% CI 4.35 to 14.28) for 0.3 mg pegaptanib, 6.25 (95% CI 4.17 to 12.5) for 1 mg pegaptanib and 14.28 (95% CI 6.67 to 100) for 3 mg pegaptanib. In a trial of ranibizumab versus sham, RR for loss of 15 or more letters visual acuity at one year was 0.14 (95% CI 0.1 to 0.22) in favour of ranibizumab. The NNT was 3.13 (95% CI 2.56 to 3.84) for 0.3 mg ranibizumab and 3.13 (95% CI 2.56 to 3.84) for 0.5 mg ranibizumab. In a trial of ranibizumab versus verteporfin PDT, RR for loss of 15 or more letters at one year was 0.13 (95% CI 0.07 to 0.23) favouring ranibizumab. The NNT was 3.33 (95% CI 2.56 to 4.76) for 0.3 mg ranibizumab and 3.12 (95% CI 2.43 to 4.17) for 0.5 mg ranibizumab. In another trial of combined ranibizumab plus verteporfin PDT versus verteporfin PDT, RR for loss of 15 or more letters at one year favoured combined therapy (RR 0.3 (95% CI 0.15 to 0.60). The NNT was 4.35 (95% CI 2.78 to 11.11). Pooled RR for gain of 15 or more letters visual acuity at one year was 5.81 (95% CI 3.29 to 10.26) for ranibizumab versus sham, 6.79 (95% CI 3.41 to 13.54) for ranibizumab/sham verteporfin PDT versus verteporfin PDT/sham ranibizumab, and 4.44 (95% CI 1.40 to 14.08) for ranibizumab plus verteporfin PDT versus verteporfin PDT. Frequency of endophthalmitis in included studies was between 0.7% to 4.7% with ranibizumab and 1.3% with pegaptanib. Improvement in vision-specific quality of life was reported for both treatments. AUTHORS' CONCLUSIONS: Pegaptanib and ranibizumab reduce the risk of visual acuity loss in patients with neovascular AMD. Ranibizumab causes gains in visual acuity in many eyes. Quality of life and cost will be important for treatment decisions. Other agents blocking VEGF are being tested in ongoing trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Senile macular degeneration: a case-control study
HYMAN, L. G., LILIENFELD, A. M., FERRIS, F. L., & FINE, S. L. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113629 · Cited by 587
Klein, R., Klein, B. E. K., Knudtson, M. D., Wong, T. Y., Cotch, M. F., Liu, K., Burke, G., Saad, M. F., & Jacobs, D. R. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.12.013 · Cited by 399
FACTORS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
GOLDBERG, J., FLOWERDEW, G., SMITH, E., BRODY, J. A., & TSO, M. O. M. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115023 · Cited by 384
Klein, R., Klein, B. E. K., Tomany, S. C., Meuer, S. M., & Huang, G.-H. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01146-6 · Cited by 363
Familial aggregation of age-related maculopathy
SEDDON, J. M., AJANI, U. A., & MITCHELL, B. D. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)71036-0 · Cited by 350
Racial differences in the prevalence of age-related macular degeneration
Friedman, D. S., Katz, J., Bressler, N. M., Rahmani, B., & Tielsch, J. M. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90267-1 · Cited by 304
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
The Genetics of Age-Related Macular Degeneration: A Review of Progress to Date
Haddad, S., Chen, C. A., Santangelo, S. L., & Seddon, J. M. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2006.05.001 · Cited by 299
Smoking and Age-Related Maculopathy: The Blue Mountains Eye Study
Smith, W. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140716016 · Cited by 255
Seddon, J. M., George, S., Rosner, B., & Klein, M. L. (2006) · Human Heredity · doi:10.1159/000094141 · Cited by 176
Research works printed but not linked: 62
- Apte, 2007, Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration, Ophthalmology, 114, 1702, 10.1016/j.ophtha.2007.02.021 · DOI
- Chang, 2007, Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial, Archives of Ophthalmology, 125, 1460, 10.1001/archopht.125.11.1460 · DOI · Paper page
- Chang, 2006, Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 Phase Iii randomized clinical trials of ranibizumab, Investigative Ophthalmology & Visual Science, 47, E-Abstract 5252
- Kaiser, 2007, Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration, Ophthalmology, 114, 1868, 10.1016/j.ophtha.2007.04.030 · DOI · Paper page
- Aggio, 2006, Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration, Acta Ophthalmologica Scandinavica, 84, 831, 10.1111/j.1600-0420.2006.00764.x · DOI
- Barouch, 2004, Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration, International Ophthalmology Clinics, 44, 23, 10.1097/00004397-200404430-00005 · doi:10.1097/00004397-200404430-00005
- Bashshur, 2007, Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration, Archives of Ophthalmology, 125, 1357, 10.1001/archopht.125.10.1357 · DOI
- 2003, Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results, Ophthalmology, 110, 979, 10.1016/S0161-6420(03)00085-X · DOI · Paper page
- Fine, 2005, Pegaptanib sodium, Nature Reviews. Drug Discovery, 4, 187, 10.1038/nrd1677 · DOI
- Hahn, 2007, Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration, Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 104, 588, 10.1007/s00347-007-1547-4 · DOI
- Heier, 2006, Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study, Ophthalmology, 113, 642. e1-4, 10.1016/j.ophtha.2005.10.052 · DOI · Paper page
- Kim, 2004, Innovative treatments for exudative age-related macular degeneration, International Ophthalmology Clinics, 44, 41, 10.1097/00004397-200404440-00005 · DOI
- Lazic, 2007, Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration, Ophthalmology, 114, 1179, 10.1016/j.ophtha.2007.03.006 · DOI
- Michels, 2005, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study, Ophthalmology, 112, 1035, 10.1016/j.ophtha.2005.02.007 · DOI · Paper page
- Nguyen, 2006, A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration, Ophthalmology, 113, 1522.e1, 10.1016/j.ophtha.2006.05.055 · DOI
- Rakic, 2005, Pegaptanib and age-related macular degeneration, New England Journal of Medicine, 352, 1720, 10.1056/NEJM200504213521619 · DOI
- Razavi, 2002, Age-related macular degeneration: A review of anti-angiogenic treatments, Journal Francais D'Ophtalmologie, 25, 747
- Rosenfeld, 2005, Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration, Ophthalmology, 112, 1048, 10.1016/j.ophtha.2005.01.043 · DOI · Paper page
- Scott, 2007, Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study - Commentary, Evidence-Based Ophthalmology, 8, 100
- Siddiqui, 2005, Pegaptanib in exudative age-related macular degeneration, Drugs, 65, 1571, 10.2165/00003495-200565110-00010 · DOI
- Campochiaro, 2004, Ocular neovascularization and excessive vascular permeability, Expert Opinion on Biological Therapy, 4, 1395, 10.1517/14712598.4.9.1395 · DOI · Paper page
- Michels, 2005, Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis, Klinische Monatsblatter Fur Augenheilkunde, 222, 480, 10.1055/s-2005-858315 · doi:10.1055/s-2005-858315
- Mills, 2007, A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects, Journal of Clinical Epidemiology, 60, 456, 10.1016/j.jclinepi.2006.09.001 · DOI
- Moshfeghi, 2005, Pegaptanib sodium for the treatment of neovascular age-related macular degeneration, Expert Opinion on Investigational Drugs, 14, 671, 10.1517/13543784.14.5.671 · DOI
- Ng, 2005, Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration, Canadian Journal of Ophthalmology, 40, 352, 10.1016/S0008-4182(05)80078-X · DOI · Paper page
- Pulido, 2002, Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat neovascular age-related macular degeneration: Interim analysis, Transactions of the American Ophthalmological Society, 100, 85
- Pulido, 2005, Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action, Canadian Journal of Ophthalmology, 40, 332, 10.1016/S0008-4182(05)80076-6 · DOI
- Sorbera, 2003, Ranibizumab: Treatment of age-related macular degeneration humanized monoclonal anti-VEGF antibody angiogenesis inhibitor, Drugs of the Future, 28, 541, 10.1358/dof.2003.028.06.738510 · doi:10.1358/dof.2003.028.06.738510
- Aiello, 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, New England Journal of Medicine, 331, 1480, 10.1056/NEJM199412013312203 · DOI · Paper page
- Avery, 2006, Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology, 113, 367, 10.1016/j.ophtha.2005.11.019 · DOI · Paper page
- Blinder, 2003, Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1, American Journal of Ophthalmology, 136, 407
- Boekhoorn, 2007, C-reactive protein level and risk of aging macula disorder: The Rotterdam Study, Archives of Ophthalmology, 125, 1396, 10.1001/archopht.125.10.1396 · DOI · Paper page
- Brown, 2007, Anti-VEGF agents in the treatment of age-related macular degeneration: applying clinical trial results to the treatment of everyday patients, American Journal of Ophthalmology, 144, 627, 10.1016/j.ajo.2007.06.039 · DOI · Paper page
- Brown, 2007, A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration, Ophthalmology, Oct 31 (Epub ah
- Bunce, 2006, Leading causes of certification for blindness and partial sight in England & Wales, BMC Public Health, 6, 58, 10.1186/1471-2458-6-58 · DOI · Paper page
- Deangelis, 2007, Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration, Archives of Ophthalmology, 125, 49, 10.1001/archopht.125.1.49 · DOI · Paper page
- Deeks JJ Higgins JPT Altman DG Analysing and presenting data. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 8] In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd
- Emerson, 2007, Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration, Retina, 27, 439, 10.1097/IAE.0b013e31804b3e15 · DOI · Paper page
- Fung, 2007, An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration, American Journal of Ophthalmology, 143, 566, 10.1016/j.ajo.2007.01.028 · DOI · Paper page
- Ghafour, 1983, Common causes of blindness and visual handicap in the west of Scotland, British Journal of Ophthalmology, 67, 209, 10.1136/bjo.67.4.209 · DOI · Paper page
- Glanville, 2006, How to identify randomized controlled trials in MEDLINE: ten years on, Journal of the Medical Library Association, 94, 130
- Higgins JPT Green S Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6 In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd
- Hyman, 1987, Epidemiology of eye disease in the elderly, Eye, 1, 330, 10.1038/eye.1987.53 · DOI
- Jager RD. Aiello, 2004, Risks of intravitreous injection: A comprehensive review, Retina, 24, 676, 10.1097/00006982-200410000-00002 · DOI · Paper page
- Klein, 2008, Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration, Archives of Ophthalmology, 126, 115, 10.1001/archopht.126.1.115 · DOI · Paper page
- Kvanta, 1996, Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor, Investigative Ophthalmology & Visual Science, 37, 1929
- Leibowitz, 1980, The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975, Survey of Ophthalmology, 24, 335
- Lopez, 1996, Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes, Investigative Ophthalmology and Visual Science, 37, 855
- Mitchell, 2002, Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study, Archives Ophthalmology, 120, 1357, 10.1001/archopht.120.10.1357 · DOI · Paper page
- 1991, Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group, Archives of Ophthalmology, 109, 1109, 10.1001/archopht.1991.01080080069030 · DOI · Paper page
- O'Shea, 1998, Age-related macular degeneration, Postgraduate Medical Journal, 74, 203, 10.1136/pgmj.74.870.203 · DOI
- Piguet, 1993, Age-related Bruch's membrane change: a clinical study of the relative role of heredity and environment, British Journal Ophthalmology, 77, 400, 10.1136/bjo.77.7.400 · DOI · Paper page
- Raftery, 2007, Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness, British Journal of Ophthalmology, 91, 1244, 10.1136/bjo.2007.116616 · DOI · Paper page
- Schaumberg, 2007, A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors, Archives of Ophthalmology, 125, 55, 10.1001/archopht.125.1.55 · DOI · Paper page
- Silvestri, 1994, Is genetic predisposition an important risk factor in age-related macular degeneration?, Eye, 8, 564, 10.1038/eye.1994.138 · DOI
- Spaide, 2006, Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration, Retina, 26, 383, 10.1097/00006982-200604000-00001 · DOI · Paper page
- Solomon, 2007, Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group, Archives of Ophthalmology, 125, 1323, 10.1001/archopht.125.10.1323 · DOI · Paper page
- 1999, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report, Archives of Ophthalmology, 117, 1329, 10.1001/archopht.117.10.1329 · DOI · Paper page
- Tielsch, 1994, Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older
- Kerckhoven, 2001, Features of age-related macular degeneration on optical coherence tomography, Bulletin de la Societe Belge d' Ophtalmologie, 281, 75
- Virgili, 2007, Laser photocoagulation for neovascular age-related macular degeneration, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004763.pub2 · DOI
- Wormald, 2007, Photodynamic therapy for nonvascular age-related macular degeneration, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD002030.pub3 · DOI · Paper page
Cited by
Evidence-based clinical guidelines for immigrants and refugees
Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N. E., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 526
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Self-citationAnti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Self-citationPredictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
Metadata
- Authors
- Vedula, S. S., & Krzystolik, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2008-04-23
- Issue
- 2
- Pages
- CD005139-CD005139
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1553160311
- Cited by
- 87
- References
- 20
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2014-08-29)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.